JUPITER NEUROSCIENCES INC (JUNS) Stock Price, Quote, News and Overview
NASDAQ:JUNS - Nasdaq - US48208B2034 - Common Stock - Currency: USD
JUNS Quote, Performance and Key Statistics
1.13
+0.01 (+0.89%)
The current stock price of JUNS is 1.13 USD. In the past month the price increased by 87.4%.
JUNS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 59.55 | 776.54B | ||
| JNJ | JOHNSON & JOHNSON | 15.63 | 377.99B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 21.87 | 354.71B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 14.37 | 235.92B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 16.91 | 230.73B | ||
| MRK | MERCK & CO. INC. | 10.49 | 205.18B | ||
| PFE | PFIZER INC | 7.64 | 139.52B | ||
| SNY | SANOFI-ADR | 10.99 | 120.88B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 6.78 | 101.25B | ||
| GSK | GSK PLC-SPON ADR | 9.14 | 82.81B | ||
| ZTS | ZOETIS INC | 27.3 | 73.16B | ||
| HLN | HALEON PLC-ADR | 21.74 | 48.91B |
Related stock screener links
About JUNS
Company Profile
Jupiter Neurosciences, Inc. is a clinical-stage pharmaceutical company engaged in treating neuroinflammation with a current focus on CNS disorders and rare diseases. The company is headquartered in Palm Beach Gardens, Florida and currently employs 4 full-time employees. The company went IPO on 2024-12-03. The firm has developed a resveratrol platform product targeting treatment of neuro-inflammation. Its product, JOTROL, has many potential indications of use for rare diseases, which of it primarily is targeting Mucopolysaccharidoses Type 1, Friedreich's Ataxia, and Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like episodes (MELAS). In the larger disease areas, the Company is primarily targeting Parkinson's Disease and Mild Cognitive Impairment/early Alzheimer’s disease. The firm has designated the different indications with project numbers, JNS101 - JNS115. JOTROL is a micellar non-aqueous solution of resveratrol delivered in a soft gel capsule. Each capsule includes 100 milligrams (mg) of resveratrol. The company has a worldwide license, from Aquanova AG, the patent holder of micellar technologies, to develop, manufacture, distribute and sell JOTROL.
Company Info
JUPITER NEUROSCIENCES INC
1001 North US HWY 1, Suite 504
Palm Beach Gardens FLORIDA US
Employees: 4
Phone: 15614066154
JUPITER NEUROSCIENCES INC / JUNS FAQ
What is the stock price of JUPITER NEUROSCIENCES INC today?
The current stock price of JUNS is 1.13 USD. The price increased by 0.89% in the last trading session.
What is the ticker symbol for JUPITER NEUROSCIENCES INC stock?
The exchange symbol of JUPITER NEUROSCIENCES INC is JUNS and it is listed on the Nasdaq exchange.
On which exchange is JUNS stock listed?
JUNS stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for JUPITER NEUROSCIENCES INC stock?
7 analysts have analysed JUNS and the average price target is 30.6 USD. This implies a price increase of 2607.96% is expected in the next year compared to the current price of 1.13. Check the JUPITER NEUROSCIENCES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is JUPITER NEUROSCIENCES INC worth?
JUPITER NEUROSCIENCES INC (JUNS) has a market capitalization of 37.40M USD. This makes JUNS a Nano Cap stock.
How many employees does JUPITER NEUROSCIENCES INC have?
JUPITER NEUROSCIENCES INC (JUNS) currently has 4 employees.
Should I buy JUPITER NEUROSCIENCES INC (JUNS) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of JUNS, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of JUNS, evaluating the profitability, health, valuation and growth aspects
- JUPITER NEUROSCIENCES INC (JUNS) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- JUPITER NEUROSCIENCES INC (JUNS) Sales and EPS estimates to see what analysts future expectations are.
- JUPITER NEUROSCIENCES INC (JUNS) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- JUPITER NEUROSCIENCES INC (JUNS) Insider and Institutional Ownership to learn about the owners and their transactions.
- JUPITER NEUROSCIENCES INC (JUNS) Stock Chart to make your own analysis
- JUPITER NEUROSCIENCES INC (JUNS) Latest news and press-releases to stay up to date.
Does JUPITER NEUROSCIENCES INC (JUNS) stock pay dividends?
JUNS does not pay a dividend.
What is the Price/Earnings (PE) ratio of JUPITER NEUROSCIENCES INC (JUNS)?
JUPITER NEUROSCIENCES INC (JUNS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.15).
What is the Short Interest ratio of JUPITER NEUROSCIENCES INC (JUNS) stock?
The outstanding short interest for JUPITER NEUROSCIENCES INC (JUNS) is 0.74% of its float. Check the ownership tab for more information on the JUNS short interest.
JUNS Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to JUNS.
JUNS Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to JUNS. JUNS scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
JUNS Financial Highlights
Over the last trailing twelve months JUNS reported a non-GAAP Earnings per Share(EPS) of -0.15.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -77.13% | ||
| ROE | -114.66% | ||
| Debt/Equity | 0.04 |
JUNS Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to JUNS. The Buy consensus is the average rating of analysts ratings from 7 analysts.